Maze Therapeutics, Inc. (NasdaqGM: MAZE)
Health Care · Pharmaceuticals · US
$30.59
+3.34% today · +122.4% 1Y
Maze Therapeutics, Inc. (NasdaqGM: MAZE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.64B and employs 141 people.
Over the last twelve months the share price has gained 122.4%, trading between 12.91 and 53.65.
Tweenvest scores Maze Therapeutics, Inc. across four factors: quality 53/100, value 49/100. Its strongest factor is quality.
MAZE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.64B
- Revenue (TTM)
- $20.00M
- P/E
- —
- EPS
- -2.52
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $53.65
- 52-week low
- $12.91
- Avg volume (3M)
- —
- Shares outstanding
- 55.55M
- Employees
- 141
- Next earnings
- —
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
- ISIN
- US5787841007
- Founded
- 2017
- Listed since
- Jan 31, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,256.27 | +0.75% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $272.62 | -0.15% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $153.48 | +1.87% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.42 | +1.61% |
Figures last refreshed Aug 18, 2026.